Dr. Reddy’s Laboratories Limited (NYSE: RDY) is -12.58% lower on its value in year-to-date trading and has touched a low of $47.88 and a high of $73.34 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The RDY stock was last observed hovering at around $57.32 in the last trading session, with the day’s loss setting it -0.14% off its average median price target of $63.59 for the next 12 months. It is also 29.14% off the consensus price target high of $80.70 offered by 35 analysts, but current levels are -1.2% lower than the price target low of $56.50 for the same period.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Sponsored
Currently trading at $57.18, the stock is 3.05% and 5.46% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.15 million and changing -0.24% at the moment leaves the stock -1.57% off its SMA200. RDY registered -21.17% loss for a year compared to 6-month loss of -9.42%. The firm has a 50-day simple moving average (SMA 50) of $54.29 and a 200-day simple moving average (SMA200) of $58.05.
The stock witnessed a 3.38% gain in the last 1 month and extending the period to 3 months gives it a 1.73%, and is 2.77% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 1.78% over the week and 1.53% over the month.
Dr. Reddy’s Laboratories Limited (RDY) has around 24795 employees, a market worth around $9.53B and $2.68B in sales. Current P/E ratio is 32.23 and Fwd P/E is 18.60. Profit margin for the company is 11.00%. Distance from 52-week low is 19.42% and -22.03% from its 52-week high. The company has generated returns on investments over the last 12 months (9.20%).
Dr. Reddy’s Laboratories Limited (RDY) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Dr. Reddy’s Laboratories Limited (RDY) is a “Buy”. 35 analysts offering their recommendations for the stock have an average rating of 1.50, where 4 rate it as a Hold and 5 think it is a “Overweight”. 26 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Dr. Reddy’s Laboratories Limited is expected to release its quarterly report on 10/28/2022.The EPS is expected to grow by 36.70% this year.
Dr. Reddy’s Laboratories Limited (RDY) Top Institutional Holders
The shares outstanding are 165.95M, and float is at 117.35M with Short Float at 1.11%.
Dr. Reddy’s Laboratories Limited (RDY): Who are the competitors?
The company’s main competitors (and peers) include Sanofi (SNY) that is -1.49% lower over the past 12 months. Pfizer Inc. (PFE) is 29.08% up on the 1-year trading charts. Short interest in the company’s stock has fallen -37.82% from the last report on Apr 28, 2022 to stand at a total of 1.37 million short shares sold with a short interest ratio of 6.31.
